FineImmu
Guangzhou
About FineImmu
FineImmu produces cell therapy drugs and immunodiagnostic products. The drug predicts the anti-tumor immune function of PD-1 and PD-L1 and the therapeutic effect of immune checkpoint inhibitors such as CTLA4. The company's contact modes are by phone and physical address.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Total funding: $13.3M
- Funding stage: Seed
- Last round: Seed (Aug 2022)
- Website: fineimmu.com
- Phone: 020-31605836
Industries & Categories
Biopharma, Biotechnology, Health Care, Medical
Canonical: https://fsome.com/organization/fineimmu-8063 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.